Fractyl Health
Fractyl Health, Inc. (Nasdaq: GUTS) is a clinical-stage metabolic therapeutics company developing treatments that target the root causes of type 2 diabetes and obesity rather than managing symptoms. Its lead product, Revita, is an outpatient endoscopic procedure that resurfaces the duodenal lining to address a driver of metabolic disease, and Rejuva is an early-stage pancreatic islet-cell gene therapy platform designed for durable, one-time metabolic remission. The company is headquartered in Massachusetts and backed by Bessemer Venture Partners and General Catalyst. Fractyl publishes no public developer API, SDK, or developer portal; this API Evangelist profile tracks its corporate, product, and investor web presence.
Fractyl Health is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Biotechnology, Metabolic Therapeutics, and Type 2 Diabetes.
Fractyl Health’s developer surface includes support and 5 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 2
The organization behind the API